Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We aimed to examine whether non-manifesting carriers of LRRK2 and GBA mutations have prodromal features of Parkinson's disease that correlate with reduced DAT binding.
|
31678032 |
2020 |
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Higher UA levels were correlated with higher dopamine transporter uptake in the putamen in female patients with early PD.
|
31446637 |
2020 |
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, cognition-related temporal atrophy might be associated with dopaminergic deficit reflected by DAT scan but independent of CSF proteins in patients with PD who convert to PD-MCI.
|
31278861 |
2020 |
Parkinson Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
IRBD patients present with an intermediate state in striatal DAT distribution and PDRP activity between PD and normal controls.
|
30741074 |
2020 |
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We analyzed longitudinal data of the specific binding ratio (SBR), a measure of striatal radiotracer uptake, in DAT SPECT from 7 patients with MSA-C, 5 patients with MSA-P, and 18 patients with PD.
|
31707374 |
2020 |
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
This review addresses the possibilities and limitations of DAT-SPECT in PD and, focusing specifically on regulatory changes of DAT in surviving DA neurons, we investigate its role in diagnosis and its prognostic value for motor complications as disease progresses.
|
31405186 |
2019 |
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
No link between striatal dopaminergic axons and dopamine transporter imaging in Parkinson's disease.
|
31234224 |
2019 |
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Additionally, all participants underwent a battery of clinical assessments to determine motor and non-motor symptoms and cognitive status, and [<sup>123</sup>I]FP-CIT single-photon emission CT (SPECT) to assess striatal dopamine transporter binding and MRI for volumetric analyses to assess whether pathology is associated with measures of Parkinson's disease burden.
|
31229470 |
2019 |
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
DAT serves as a site of action for a variety of addictive and therapeutic reuptake inhibitors, and transport dysfunction is associated with transmitter imbalances in disorders such as schizophrenia, attention deficit hyperactive disorder, bipolar disorder, and Parkinson disease.
|
30179648 |
2019 |
Parkinson Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In a macaque model of PD, also based on delivery of AAV1/2-hourA53T-aSyn to the SN, trehalose (2.67 g/kg per day, by mouth), administered for 142 days, produced higher striatal dopamine (by 39%) and dopamine transporter levels (by 50%), compared with macaques receiving vehicle.
|
30918068 |
2019 |
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
However, the combination of the two genotypes 10R/10R (rs28363170) and A carrier (rs393795) of the DAT gene reduces the risk of LID occurrence during long-term therapy with l-DOPA with respect to the PD subjects who did not carry these alleles (OR = 0.31; 95% CI, 0.09-0.88).
|
30316985 |
2019 |
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
To determine whether a multiparametric scoring system (MSS) could improve accuracy compared to each parameter of DAT-SPECT and NmMRI in differentiating PD from NDPS.
|
29804474 |
2019 |
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
We investigated the association of striatal dopamine transporter (DAT) loss with cognitive function and cerebral cortical metabolism in PD.
|
31584466 |
2019 |
Parkinson Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In patients with PD, serum IGF-1 levels were negatively correlated with age and modified Rankin scale (mRS) scores and positively correlated with the striatal dopamine transporter-specific binding ratio and the frontal assessment battery score.
|
30903695 |
2019 |
Parkinson Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to evaluate a possible relationship between DRD2/ANKK1 (rs1800497) and SLC6A3/DAT1 (rs28363170) gene polymorphisms with the response to levodopa (L-DOPA)-therapy in patients with Parkinson's disease (PD).
|
30353564 |
2019 |
Parkinson Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The objective of this study is to identify the dopamine transporter activity of the corpus striatum and thalamus according to myocardial <sup>123</sup>I-MIBG uptake in PD.
|
30796009 |
2019 |
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Impairments in gait kinematics and postural control may not correlate with dopamine transporter depletion in individuals with mild to moderate Parkinson's disease.
|
30589477 |
2019 |
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
6-OHDA is a neurotoxin widely used in PD animal models due to its high affinity by dopamine transporter, its rapid non-enzymatic auto-oxidation which generates reactive oxygen species (ROS), oxidative stress, and for induced mitochondrial dysfunction.
|
30417317 |
2019 |
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The laterality of the specific binding ratio (SBR) for dopamine transporter single-photon emission computed tomography may be useful for estimation of reduced dopamine transporter density in striatum of patients with Parkinson's disease.
|
31568269 |
2019 |
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
We hypothesised that striatal dopamine transporter (DAT) density at the time of diagnosis might play an important role in weight regulation in patients with PD.
|
31102003 |
2019 |
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
"Depressed" caudate and ventral striatum dopamine transporter availability in de novo Depressed Parkinson's disease.
|
31377233 |
2019 |
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
<b>Conclusion:</b> Striatal presynaptic DAT function is clearly lower in PSP patients than in PD and MSA-P patients and is clearly lower in MSA-P patients than in MSA-C patients.
|
30979821 |
2019 |
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Striatal DAT and extrastriatal SERT binding in early-stage Parkinson's disease and dementia with Lewy bodies, compared with healthy controls: An <sup>123</sup>I-FP-CIT SPECT study.
|
30884365 |
2019 |
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Basal ganglia DAT uptake was similar between MCI-P and PD-MOT.
|
30611093 |
2019 |
Parkinson Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
We report that the relationship of dopamine transporter availability with global cognition in Parkinson's disease is mediated by physical activity.
|
30722964 |
2019 |